Redefine your XLH treatment with a targeted therapy

X-linked hypophosphatemia (XLH) is a disease where the body doesn’t retain enough phosphorus. Phosphorus is important for bone health, and when there is not enough phosphorus, bones can weaken over time.

CRYSVITA is an FDA-approved therapy that can help the body retain phosphorus and has been evaluated for efficacy and safety in adults and children with XLH.

CRYSVITA (burosumab-twza) logo
Ask your doctor if CRYSVITA may be right for you

CRYSVITA is the only FDA-approved treatment for X-linked hypophosphatemia (XLH) that targets the underlying cause of the disease.

Attend an educational event to learn more about CRYSVITA and talk to your doctor about whether CRYSVITA is right for you or your child.

See All Patient Events
Learn about how CRYSVITA may work to help restore phosphorus levels

How CRYSVITA may work

Understand how CRYSVITA may work to help restore phosphorus levels

Learn More
UltraCare Patient Services provides information about how to access CRYSVITA
UltraCare Patient Services provides information about how to access CRYSVITA

Need access to CRYSVITA?

UltraCare Patient Services for CRYSVITA is a program that provides information about how to access CRYSVITA.

Our services are designed to help you understand your insurance coverage and tell you if you are eligible for financial and patient assistance programs that can help make CRYSVITA affordable.

Please note a completed Start Form is required for enrollment.

Visit UltraCare for CRYSVITA

XLH is a chronic bone disease that affects the lives of children and adults.

XLH patients, Sarah and Aly

CRYSVITA® (burosumab-twza) is for patients with XLH

XLH patients, Sarah and Aly

XLH is a chronic bone disease that affects the lives of children and adults.